Equities Analysts Set Expectations for CAS Medical Systems, Inc.’s Q3 2017 Earnings (CASM)

CAS Medical Systems, Inc. (NASDAQ:CASM) – Investment analysts at Zacks Investment Research dropped their Q3 2017 earnings estimates for shares of CAS Medical Systems in a report released on Monday. Zacks Investment Research analyst B. Marckx now anticipates that the medical technology company will earn ($0.09) per share for the quarter, down from their prior forecast of ($0.06). Zacks Investment Research also issued estimates for CAS Medical Systems’ Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.36) EPS, FY2018 earnings at ($0.23) EPS and FY2019 earnings at ($0.11) EPS.

COPYRIGHT VIOLATION WARNING: “Equities Analysts Set Expectations for CAS Medical Systems, Inc.’s Q3 2017 Earnings (CASM)” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.themarketsdaily.com/2017/08/19/equities-analysts-set-expectations-for-cas-medical-systems-inc-s-q3-2017-earnings-casm.html.

CAS Medical Systems (CASM) opened at 0.96 on Thursday. The stock’s market capitalization is $26.24 million. CAS Medical Systems has a 12-month low of $0.80 and a 12-month high of $1.94. The company has a 50 day moving average of $1.12 and a 200-day moving average of $1.24.

CAS Medical Systems (NASDAQ:CASM) last posted its earnings results on Tuesday, August 8th. The medical technology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.02. The company had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $5.41 million.

A hedge fund recently bought a new stake in CAS Medical Systems stock. Stonepine Capital Management LLC acquired a new stake in shares of CAS Medical Systems, Inc. (NASDAQ:CASM) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 900,366 shares of the medical technology company’s stock, valued at approximately $1,044,000. CAS Medical Systems makes up approximately 0.6% of Stonepine Capital Management LLC’s holdings, making the stock its 23rd largest position. Stonepine Capital Management LLC owned approximately 3.29% of CAS Medical Systems at the end of the most recent quarter. 26.71% of the stock is owned by institutional investors and hedge funds.

About CAS Medical Systems

CAS Medical Systems, Inc is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products for patient care. The Company designs, manufactures and distributes the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. It operates through Tissue Oximetry Monitoring, which includes sales of its FORE-SIGHT tissue oximeter monitors, sensors and accessories.

Earnings History and Estimates for CAS Medical Systems (NASDAQ:CASM)

Receive News & Ratings for CAS Medical Systems Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CAS Medical Systems Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

four × 1 =